Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: DENND4C

Gene summary for DENND4C

Gene summary.

Gene information	Species	Human
	Gene symbol	DENND4C
	Gene ID	55667
	Gene name	DENN domain containing 4C
	Gene Alias	C9orf55
	Cytomap	9p22.1
	Gene Type	protein-coding
	GO ID	GO:0006810
	UniProtAcc	Q5VZ89

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
55667	DENND4C	CCI_1	Human	Cervix	CC	9.71e-04	5.81e-01	0.528
55667	DENND4C	CCI_2	Human	Cervix	CC	1.50e-08	1.13e+00	0.5249
55667	DENND4C	CCI_3	Human	Cervix	CC	1.44e-08	7.96e-01	0.516
55667	DENND4C	HTA11_347_2000001011	Human	Colorectum	AD	8.10e-11	5.74e-01	-0.1954
55667	DENND4C	HTA11_99999965104_69814	Human	Colorectum	MSS	1.14e-02	5.73e-01	0.281
55667	DENND4C	HTA11_99999974143_84620	Human	Colorectum	MSS	1.47e-03	-3.49e-01	0.3005
55667	DENND4C	A002-C-010	Human	Colorectum	FAP	3.23e-02	4.66e-02	0.242
55667	DENND4C	A001-C-207	Human	Colorectum	FAP	4.08e-03	-1.46e-01	0.1278
55667	DENND4C	A015-C-203	Human	Colorectum	FAP	1.33e-34	-3.50e-01	-0.1294
55667	DENND4C	A015-C-204	Human	Colorectum	FAP	5.88e-07	-3.27e-01	-0.0228
55667	DENND4C	A014-C-040	Human	Colorectum	FAP	3.24e-03	-2.28e-01	-0.1184
55667	DENND4C	A002-C-201	Human	Colorectum	FAP	1.70e-13	-2.98e-01	0.0324
55667	DENND4C	A002-C-203	Human	Colorectum	FAP	1.29e-03	-9.22e-02	0.2786
55667	DENND4C	A001-C-119	Human	Colorectum	FAP	6.02e-06	-2.52e-01	-0.1557
55667	DENND4C	A001-C-108	Human	Colorectum	FAP	4.40e-18	-1.63e-01	-0.0272
55667	DENND4C	A002-C-205	Human	Colorectum	FAP	1.43e-23	-4.11e-01	-0.1236
55667	DENND4C	A001-C-104	Human	Colorectum	FAP	3.70e-02	-1.14e-01	0.0184
55667	DENND4C	A015-C-005	Human	Colorectum	FAP	5.02e-03	-2.85e-01	-0.0336
55667	DENND4C	A015-C-006	Human	Colorectum	FAP	3.11e-19	-5.17e-01	-0.0994
55667	DENND4C	A015-C-106	Human	Colorectum	FAP	4.96e-12	-1.61e-01	-0.0511

Page: 1 2 3 4 5 6 7 8

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:199077820	Skin	AK	protein localization to cell periphery	66/1910	333/18723	9.18e-08	4.21e-06	66
GO:004343425	Skin	AK	response to peptide hormone	69/1910	414/18723	2.87e-05	4.98e-04	69
GO:007137517	Skin	AK	cellular response to peptide hormone stimulus	52/1910	290/18723	3.86e-05	6.35e-04	52
GO:190165320	Skin	AK	cellular response to peptide	61/1910	359/18723	4.60e-05	7.21e-04	61
GO:003286919	Skin	AK	cellular response to insulin stimulus	39/1910	203/18723	7.61e-05	1.07e-03	39
GO:005105615	Skin	AK	regulation of small GTPase mediated signal transduction	48/1910	302/18723	1.28e-03	9.69e-03	48
GO:003286819	Skin	AK	response to insulin	43/1910	264/18723	1.37e-03	1.02e-02	43
GO:004657810	Skin	AK	regulation of Ras protein signal transduction	33/1910	189/18723	1.49e-03	1.08e-02	33
GO:0072659111	Skin	SCCIS	protein localization to plasma membrane	32/919	284/18723	1.07e-05	3.77e-04	32
GO:005105616	Skin	SCCIS	regulation of small GTPase mediated signal transduction	33/919	302/18723	1.49e-05	4.86e-04	33
GO:1990778110	Skin	SCCIS	protein localization to cell periphery	35/919	333/18723	1.93e-05	5.84e-04	35
GO:000726517	Skin	SCCIS	Ras protein signal transduction	35/919	337/18723	2.48e-05	6.96e-04	35
GO:0043434112	Skin	SCCIS	response to peptide hormone	38/919	414/18723	1.63e-04	3.28e-03	38
GO:004657816	Skin	SCCIS	regulation of Ras protein signal transduction	21/919	189/18723	4.08e-04	6.62e-03	21
GO:007265926	Skin	cSCC	protein localization to plasma membrane	118/4864	284/18723	6.43e-09	2.11e-07	118
GO:199077824	Skin	cSCC	protein localization to cell periphery	134/4864	333/18723	7.09e-09	2.30e-07	134
GO:000726523	Skin	cSCC	Ras protein signal transduction	132/4864	337/18723	6.17e-08	1.57e-06	132
GO:004343426	Skin	cSCC	response to peptide hormone	150/4864	414/18723	2.11e-06	3.43e-05	150
GO:007137518	Skin	cSCC	cellular response to peptide hormone stimulus	104/4864	290/18723	1.15e-04	1.06e-03	104
GO:1901653110	Skin	cSCC	cellular response to peptide	124/4864	359/18723	1.75e-04	1.49e-03	124

Page: 1 2 3 4 5 6 7 8 9

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

DENND4C

SNV

Missense_Mutation

c.950N>T

p.Ser317Leu

p.S317L

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-A2-A0T2-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

xeloda

DENND4C

SNV

Missense_Mutation

c.2723N>G

p.Ser908Cys

p.S908C

protein_coding

deleterious(0.02)

possibly_damaging(0.754)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DENND4C

SNV

Missense_Mutation

c.1828N>T

p.Arg610Cys

p.R610C

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DENND4C

SNV

Missense_Mutation

c.5516N>T

p.Arg1839Met

p.R1839M

protein_coding

deleterious(0)

probably_damaging(0.975)

TCGA-BH-A0AY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

DENND4C

SNV

Missense_Mutation

c.2254G>A

p.Glu752Lys

p.E752K

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-BH-A1FN-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

DENND4C

SNV

Missense_Mutation

c.3698G>C

p.Ser1233Thr

p.S1233T

protein_coding

deleterious(0.01)

possibly_damaging(0.831)

TCGA-C8-A27B-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

DENND4C

insertion

Frame_Shift_Ins

novel

c.3706_3707insAT

p.Gly1236AspfsTer16

p.G1236Dfs*16

protein_coding

TCGA-A8-A07R-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Ancillary

zoledronic

DENND4C

insertion

Nonsense_Mutation

novel

c.3707_3708insAGAATCCTAAATATGAA

p.Ile1237GlufsTer3

p.I1237Efs*3

protein_coding

TCGA-A8-A07R-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Ancillary

zoledronic

DENND4C

insertion

Frame_Shift_Ins

novel

c.1458_1459insTACTCTCTGAACCCTCAGCTGTACCACTGCTGTACTTA

p.Ile487TyrfsTer13

p.I487Yfs*13

protein_coding

TCGA-AO-A128-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

DENND4C

SNV

Missense_Mutation

rs772654971

c.1702N>T

p.Arg568Cys

p.R568C

protein_coding

tolerated(0.15)

probably_damaging(0.928)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1